

Cognitive behavioural therapy combined with exercise training for adults with both insomnia and obstructive sleep apnea

Submission date 23/02/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 04/04/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 31/03/2022	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Individuals with both obstructive sleep apnea (OSA) and chronic insomnia report difficulty falling asleep and staying asleep in addition to breathing difficulty when they are asleep. This group of individuals shows worse daytime functioning and fatigue in comparison to individuals with only one of the two disorders. Cognitive behavioural therapy for insomnia (CBTi) is a proven treatment for insomnia but will not improve OSA severity alone. A new therapy to target both disorders is warranted. Research suggests that exercise improves subjective sleep quality and breathing patterns in individuals with insomnia and OSA, respectively. Our goal is to assess whether a combination of exercise and CBTi will improve insomnia symptoms in individuals with both OSA and insomnia.

Who can participate?

Adults over the age of 18 with both insomnia disorder and mild to moderate obstructive sleep apnea.

What does the study involve?

Participants will be randomly assigned to either receive digital relaxation therapy for eight weeks followed by eight more weeks of CBTi and exercise training or to receive exercise training for the full 16 weeks. Participants in both groups will be required to come in for a total of three overnight recordings and three cardiopulmonary exercise tests at pre-treatment, mid-treatment, and post-treatment.

What are the possible benefits and risks of participating?

Participants in both treatment groups may benefit from improved sleep and improved physical fitness from the treatment.

The risks associated with participation in this study are no greater than the risks associated with routine psychological or medical tests. The risks for each study task are described below:

- Questionnaires: mild discomfort while answering questions of a personal nature;

- Heart rate and brain activity recordings: mild skin irritation from the electrodes placed on the skin;
- Exercise testing and training: engaging in physical activity may result in discomfort generally related to the exercise: fatigue, breathlessness, dryness in the mouth. These discomforts rapidly subside when the activity is stopped. It is possible that participants may develop muscle or joint pain requiring them to temporarily stop exercising. There is also a risk of injury associated with high volumes of physical exercise. Participants will also be taught proper form for resistance training and stretching exercises, and be advised on the types of exercise to favor given their build, with consideration for their preferences.

Where is the study run from?

Concordia University, Montreal, Canada

When is the study starting and how long is it expected to run for?

June 2017 to November 2020

Who is funding the study?

This study is funded by Breathing As One: Allied Health Research Grant from the Lung Association and PERFORM's Innovative Research Project in Preventive Health. (Canada)

Who is the main contact?

Dr Veronique Pepin

veronique.pepin@concordia.ca

514-848-2424 # 5806

Contact information

Type(s)

Principal Investigator

Contact name

Prof Véronique Pepin

ORCID ID

<http://orcid.org/0000-0002-3446-153X>

Contact details

Department of Health, Kinesiology and Applied Physiology

S.P. Building 165.03

Concordia University

7141 rue Sherbrooke Ouest

Montréal

Canada

H4B 1R6

+1 514-8482424 ext 5806

veronique.pepin@concordia.ca

Type(s)

Principal Investigator

Contact name

Prof Jean-Philippe Gouin

Contact details

Department of Psychology
Concordia University
PY Building, Office 170-14
7141 Sherbrooke Street West
Montreal
Canada
H4B1R6
+1 514-848-2424 ext 7538
jp.gouin@concordia.ca

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

A pilot randomized trial of combined cognitive behavioural therapy & exercise training versus exercise training alone for the treatment of co-morbid insomnia disorder and obstructive sleep apnea.

Acronym

APNex

Study objectives

Primary outcome:

During the first phase of the study, the exercise training alone group will be associated with larger decrease in the Insomnia Severity Index, compared to the relaxation group. During the second phase of the study, the combined CBTi plus exercise training intervention group will show larger decrease in the Insomnia Severity Index, compared to the exercise training alone group.

Secondary outcomes:

During the first phase of the study, the exercise training alone group will be associated with larger increase in cardiopulmonary fitness, as assessed by VO2 peak during a cardiopulmonary exercise test, compared to the relaxation group. During the second phase of the study, the combined CBTi plus exercise training intervention group will show similar increase in VO2 peak, compared to the exercise training alone group.

During the first phase of the study, the exercise training alone group will be associated with larger decrease in the oxygen desaturation index during the overnight polysomnography, compared to the relaxation group. During the second phase of the study, the combined CBTi plus exercise training intervention group will show similar decrease in the oxygen desaturation index, compared to the exercise training alone group.

During the first phase of the study, the exercise training alone group will be associated with a larger decrease in cumulative time spent below 90% SpO₂ during the overnight polysomnography, compared to the relaxation group. During the second phase of the study, the combined CBTi plus exercise training intervention group will show similar decrease in the cumulative time spent below 90% SpO₂, compared to the exercise training alone group.

During the first phase of the study, the exercise training alone group will be associated with higher sleep efficiency during the overnight polysomnography, compared to the relaxation group. During the second phase of the study, the combined CBTi plus exercise training intervention group will show higher increase in sleep efficiency during the overnight polysomnography, compared to the exercise training alone group.

During the first phase of the study, the exercise training alone group will be associated with a larger decrease in BMI, compared to the relaxation group. During the second phase of the study, the combined CBTi plus exercise training intervention group will show similar decrease in BMI, compared to the exercise training alone group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 25/07/2017, Concordia University Human Research Ethics Committee (Office of Research – Research Ethics and Compliance Unit: GM 900, Montreal, Quebec, Canada; +1 514.848.2424 ex. 7481; oor.ethics@concordia.ca), ref: 30007287

Study design

Single-centre interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Treatment for comorbid chronic insomnia and obstructive sleep apnea.

Interventions

This study is a 16-week randomized controlled trial. Participants are randomized to receive either relaxation therapy for eight weeks followed by a combination of cognitive-behavioural therapy for insomnia and exercise training for the second eight weeks (CBTi-Ex group) or 16 weeks of exercise training alone (Ex group) using a 1:1 allocation ratio. At the pre-treatment baseline, after phase 1 (mid-treatment) and after phase 2 (post-treatment), participants will complete self-report measure of insomnia severity, overnight polysomnography, as well as a symptom-limited cardiopulmonary exercise test on a cycle ergometer. Randomization will be conducted by block of 4 to ensure similar group size in this pilot study.

The CBTi component of treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The applied relaxation treatment during phase 1 of the CBTi-Ex group includes self-guided digital audio-recordings of relaxation exercises to be completed at home at least 3 times per week. The relaxation exercises include exercise diaphragmatic breathing, progressive muscle relaxation and guided imagery.

The exercise component of treatment involves three weekly 60-minute sessions of structured moderate-intensity aerobic exercise and individualized resistance training. The aerobic training component includes 5 minutes of warm-up, followed by 40 minutes of aerobic exercise (walking, cycling, elliptical, etc.) performed at a heart rate corresponding to the ventilatory threshold, and 5 minutes of cool-down. The resistance training component consists of 1 set of 12–15 repetitions for 6-8 different exercises. One weekly session is supervised with a licensed kinesiologist, and two sessions are completed at home or in the community.

Intervention Type

Behavioural

Primary outcome measure

Insomnia severity is assessed using the Insomnia Severity Index (ISI) questionnaire at baseline, following phase 1 (8 weeks) and following phase 2 (16 weeks)

Secondary outcome measures

1. Peak oxygen consumption (VO₂ peak) during a symptom-limited cardiopulmonary exercise test on a cycle ergometer conducted at pre-treatment, mid-treatment (8 weeks), and post-treatment (16 weeks).
2. Oxygen desaturation index during the overnight polysomnography conducted at pre-treatment, mid-treatment, and post-treatment.
3. Cumulative time spent below 90% SpO₂ during the overnight polysomnography conducted at pre-treatment, mid-treatment, and post-treatment.
4. Sleep efficiency (i.e. the ratio of total sleep time overtime over the time spent in bed) during overnight polysomnography at pre-treatment, mid-treatment, and post-treatment.
5. Body mass index (BMI; kg/m²) measured at pre-treatment, mid-treatment, and post-treatment.

Overall study start date

25/06/2017

Completion date

12/11/2020

Eligibility

Key inclusion criteria

1. Meeting diagnostic criteria for a DSM-5 insomnia disorder.
2. Diagnosed with mild to moderate obstructive sleep apnea (AHI 30/h during baseline polysomnography).

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

20

Total final enrolment

20

Key exclusion criteria

1. Younger than 18 years old
2. Current neurological disorder
3. Past history of brain lesion
4. Major surgery (i.e., requiring general anesthesia) in the past 3 months
5. Untreated thyroid disorder
6. Chronic pain syndrome self-reported as interfering with sleep
7. Recent and severe infection in the past 3 months (e.g., pneumonia, kidney infection)
8. Active cancer or treated cancer with post-cancer treatment for less than 2 years
9. Stroke
10. Myocardial infarct
11. Arterial bypass or angioplasty (coronary, carotid, femoral, etc)
12. Use of a pacemaker
13. Heart failure causing limitation of ordinary physical activity
14. Renal insufficiency
15. Restless legs syndrome with symptoms 3 days or more per week (based on RLS questionnaire)
16. Periodic limb movements during sleep with index > 15/h during polysomnography
17. REM-sleep behavior disorder with more than 1 episode/month (based on screening questionnaire and PSG)
18. Narcolepsy with cataplexy
19. Sleepwalking more than once per month
20. Having worked on night shifts or rotating shifts for more than 2 weeks in the last 3 months or expecting to do so during the study period
21. Poor cognitive function (diagnosed dementia and/or MOCA less than 26)
22. Severe mental disorders:
 - 22.1 Bipolar disorder (Type I)
 - 22.2 Schizophrenia past or anxiety disorder
 - 22.3 Anxiety disorders other than GAD if not associated with MDD: Exclude.
 - 22.4 Current Substance use disorder
 - 22.5 Current post-traumatic stress disorder
23. Current Suicidality

- 24. Frequent alcohol consumption (>10 glasses/week) or use of illicit drugs (more than once a month)
- 25. Pregnant or breastfeeding women
- 26. Current psychotherapy or past CBTi
- 27. Unable to stop hypnotic medications for at least 2 weeks prior to the first assessment (e.g., benzodiazepines, zolpidem, zopiclone, quetiapine, antihistamines)
- 28. Currently engaging in moderate or vigorous physical activity for over 150 minutes per week.

Date of first enrolment

25/07/2017

Date of final enrolment

02/03/2020

Locations

Countries of recruitment

Canada

Study participating centre

PERFORM center

7141 Sherbrooke St. W.

Montreal

Canada

H4B 1R6

Sponsor information

Organisation

Concordia University

Sponsor details

7141 Sherbrooke St. W.

Montreal

Canada

H4B1R6

+1 514-848-4544

oor.ethics@concordia.ca

Sponsor type

University/education

Website

<https://www.concordia.ca/>

ROR

<https://ror.org/0420zv78>

Funder(s)

Funder type

Charity

Funder Name

The Lung Association (Breathing As One: Allied Health Research Grant)

Funder Name

PERFORM Centre (Innovative Research Project in Preventive Health)

Results and Publications

Publication and dissemination plan

Two to three articles are planned to be published: the main one on the effects of the intervention on insomnia severity, sleep, and cardiorespiratory fitness. A second one on the effects of the interventions on objectively-measured physical activity levels. And a third one on the effects of exercise training on exercise recovery.

Intention to publish date

01/01/2022

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Véronique Pepin at veronique.pepin@concordia.ca.

-Type of data: outcome data.

-When the data will become available and for how long: on demand until 2026.

-By what access criteria data will be shared including with whom: researchers from public institutions (university or research centre).

-For what types of analyses: systematic reviews and meta-analyses.

-By what mechanism: contact the principal investigator by email.

-Whether consent from participants was obtained: no.

-Comments on data anonymisation: all data is identified only with a code with no identifying information.

IPD sharing plan summary

Available on request